Cipla (CIPLA IN): Q3FY24 Result- Continued Growth Trajectory Across Key Markets; Positive Outlook
​Cipla reports strong Q3FY24 result with 14% YoY sales growth and 24.2% EBITDA margin. US business achieves record high sales. Full-year EBITDA...
582 Views
CIPLA Ltd - Healthy Performance on All Parameters
The company’s US revenue stood at $230 Mn (vs. exp $220 Mn) and was led by improvement in the base business pricing and higher MS in Lenotirade,...
273 Views
Emcure Pharmaceuticals Pre-IPO: IPO Size Trimmed; Domestic Revenue Growth Decelerated
Emcure has re-flied DRHP for the second time and is looking to raise $400–500M through fresh issue and an OFS of ~14M shares. IPO proceeds will be...
1k Views
Mankind Pharma Placement - Its Expensive, but at Least It’s High Quality
A group of shareholders is looking to raise around US$600m via selling a 6.9% stake in Mankind Pharma. We had looked at the lockup release earlier.
741 Views
Torrent Pharmaceuticals (TRP IN): Q2FY24 Result- Domestic Business Continued Solid Growth Path
​Torrent reported 16% revenue growth in Q2, led by India, where outperformance continued due to strong growth in chronic therapies, gastro demand...
525 Views